-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
WHO WE HELP
-
Pharmaceutical Manufacturers
-
Emerging Biopharma
-
MedTech
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MorePharmaceutical Manufacturers
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsMedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover More
Medical Specialty and Patient Advocacy
Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Explore NowU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTS
Blog
Trends to Watch through 2023: Policy changes after pricing and reimbursement
Mar 21, 2022
As we launch into 2022, it’s time for our stakeholders to look ahead and begin making and adjusting their yearly goals. It will be important to explore what trends in pharma are developing and how they may impact those working in the industry. In this blog series, we will explore the top seven trends we see emerging in 2022 and 2023, and how our customers should respond.
In this first blog, we will explore how policy changes around pricing and reimbursement will affect the healthcare ecosystem.
Policy changes after pricing and reimbursement
While constant rumblings by Congress and shifting administrations to address drug pricing issues have failed to materialize in concrete legislation, changes in drug pricing policies continue to be an industry wild card. Current Centers for Medicare and Medicaid Services (CMS) forecasts for Medicare solvency sit at historic lows as budget pressures the existing framework (Figure 1).
Figure 1
Recent precedents with the legal challenges to CMS rules indicate that the path forward for true, substantive, reform lies with the legislative pathway. As reforms like rebate safe harbor removal, international reference pricing, and drug reimportation get debated, new bipartisan ideas have begun to emerge. One such area where there is both Democrat and Republican support lies in Medicare benefit redesign.
Cracks in the current Medicare Part D benefit design have been exposed as the market has evolved over the past decade. Patients on specialty drugs quickly move through the Coverage Gap phase and into catastrophic coverage, where CMS picks up 80% of the cost, patients are faced with high cost sharing requirements causing many to forgo treatment, payer pay is minimal for many drugs pushing liability to CMS, and Coverage Gap liabilities disproportionately impact retail brands (Figure 2).
Figure 2
Recent policy frameworks introduced by house democrats and senate republicans demonstrate that there is general overlap in proposed redesigns. While the actual percentages of liabilities vary across patient, payer, manufacturer, and CMS, there is room for negotiating a path forward. That path will likely see a shifting of responsibility from patients and CMS to manufacturers and payers. New liabilities and incentives will create the need for market adjustments to address the changing dynamics. Payers will likely seek to tighten formularies even more, and manufacturers must prepare for an upward shift in specialty product liabilities and potentially extend liabilities to include prescriptions filled by low income subsidy patients. Patients will benefit as new out-of-pocket spending caps are introduced, which will make it easier to stay on higher cost therapies throughout the year versus enduring the copay fluctuations many experience under today’s design.
The effects of policy change will be long-lasting and will have many intended, and unintended, outcomes. The shifting of responsibility from CMS back to manufacturers and payers will help improve Medicare solvency but will come at a cost of billions of dollars annually for which CMS currently holds responsibility.
In our next blog, we will explore Copay Accumulator Adjuster Programs.
Top Issues for Pharma to Watch in 2022 and 2023
Coming out of the global COVID-19 pandemic, the future holds both opportunity and increased complexity for the pharmaceutical industry. There are many important issues for pharma to watch in the near future as economic factors will continue to put pressure on revenue and margins. Seven important issues for pharma to watch in 2022 and 2023 that focus on policy, payer, and patients are explored during this webinar.